Professional antigen-presenting cells that recognize tumor antigens and present them to T cells, bridging innate and adaptive immunity.
Explore the Antigen Presentation Theatre ↓Dendritic cells (DCs) are the immune system's professional antigen-presenting cells. They capture, process, and present tumor and pathogen antigens to T cells via MHC molecules, initiating a personalized, targeted immune response. They are the most critical cell type bridging innate and adaptive immunity.
Click the numbered hotspots on the left to examine the molecular toolkit of a dendritic cell.
Star-shaped cytoplasmic projections
The long, branching cytoplasmic extensions that give the cell its characteristic shape. They dramatically increase surface area, maximizing antigen capture efficiency. A single DC can interact with thousands of T cells simultaneously.
HLA-DR, HLA-DP, HLA-DQ
Major histocompatibility complex class II molecules that present processed antigen peptides to CD4+ T cells. Surface expression increases 10-100 fold upon DC maturation — a hallmark of antigen presentation capacity.
CD80 (B7-1), CD86 (B7-2), CD40
The "second signal" molecules required for T cell activation. Without them, T cells become anergic (unresponsive). DCs' ability to upregulate these molecules at high levels is the critical feature that distinguishes them from other antigen- presenting cells.
IL-12, IL-6, IFN-α, TNF-α
The DCs' "third signal" — cytokines secreted by DCs determine the differentiation fate of T cells. IL-12 drives Th1 (anti-tumor) responses; IL-4 drives Th2 (humoral) responses. The anti-tumor cytokine profile of mature DCs is the molecular basis of cancer immunotherapy.
Endosome & phagolysosome
DCs capture extracellular antigens via macropinocytosis, phagocytosis, and receptor-mediated endocytosis. Within these vesicles, antigens are broken down into peptide fragments and loaded onto MHC molecules. DCs' cross-presentation capability allows them to display extracellular antigens on MHC-I to CD8+ T cells — critical for anti-tumor immunity.
The 4-act story of how dendritic cells bridge innate and adaptive immunity. In each scene, the DC dons a different molecular costume and lays the foundation of an anti-tumor response. Click on a scene to explore the details.
A silent guard, walking the depths of every tissue.
Immature dendritic cells reside in every tissue, from skin to gut. Their task is simple: continuously survey the environment and sample anything suspicious. At this stage they are not yet "teachers" — just watchers.
The cell is completely reprogrammed.
A tumor cell breaks open or a pathogen signal (DAMP, PAMP) is released. The DC senses this through its Toll-like receptors and begins to transform within minutes. MHC-II and costimulator molecules increase 10-100 fold, phagocytic capacity drops. It is no longer an antigen catcher — it is now an antigen-presenting machine.
It sets out to deliver the message to millions of T cells.
The maturing DC carries the chemokine receptor CCR7 to its surface and slips into the lymphatic vessels. It reaches the nearest lymph node within roughly 6 to 24 hours. This is the paracortex, where thousands of naive T cells gather — the stage where anti-tumor training will take place.
DC and T cell meet face to face. Training begins.
The DC comes face to face with a naive T cell. A specialized contact zone called the immunological synapse forms between them. Three signals are delivered simultaneously; without all three, the T cell becomes anergic and cannot activate.
Outcome: Tumor-specific cytotoxic T cells expand, and long-lived memory T cells form. This is the ultimate deliverable of a personalized cancer vaccine.
Starting from the patient's own monocytes, an antigen-loaded, mature, clinical-grade DC product in ~7 days. Each step sits at the intersection of cell biology and immunology textbooks.
Purification of the starting cells
Leukapheresis collects peripheral blood mononuclear cells (PBMCs) from the patient. Monocytes are isolated via plastic adherence, magnetic bead selection (CD14+), or elutriation — these monocytes are the raw material of DC differentiation. A typical apheresis yields 5-10×10⁹ PBMCs.
Transformation in IL-4 + GM-CSF cocktail
Monocytes are cultured for 5 days in medium containing GM-CSF (granulocyte-macrophage colony-stimulating factor) and IL-4. During this time the cells morphologically transform into "star-shaped" immature DCs: CD14 is lost and CD11c, MHC-II, and the mannose receptor appear on the surface. The cell is now ready to capture antigen.
Tumor antigen + maturation cocktail
Patient-specific tumor antigen is loaded onto immature DCs (lysate, peptide, mRNA electroporation, or viral vector). A classic maturation cocktail (TNF-α + IL-1β + IL-6 + PGE₂) is then added to fully mature the DCs: CD80/86, CD83, and CCR7 reach maximum surface expression. After quality control, the product is administered intradermally / subcutaneously / intranodally.
DC-based cancer vaccines have shown meaningful survival benefits in hundreds of clinical trials since the FDA approval (Sipuleucel-T, 2010).
Sipuleucel-T (commercial name Provenge®) is a cancer vaccine prepared from the patient's own dendritic cells. The U.S. FDA approved it in 2010 for hormone-resistant metastatic prostate cancer (mCRPC).
Phase 3 IMPACT trial — 512 patients, 2:1 randomization:
• Median survival: vaccine arm 25.8 months, control 21.7 months — 4.1-month extension (Hazard Ratio 0.78; 95% confidence interval: 0.61–0.98; P=0.03)
• 36-month survival rate: 31.7% vs 23.0%, favoring vaccine
Bottom line: Sipuleucel-T is the first FDA-approved cellular cancer vaccine in history. This trial proved that dendritic cell therapy can extend life in real patients — a clinical milestone for the field.
Kantoff et al., N Engl J Med, 2010; 363:411-422The U.S. registry of all clinical research, ClinicalTrials.gov, lists 300+ DC-based cancer vaccine trials. Most studied cancer types:
• Brain cancer (glioblastoma)
• Skin cancer (melanoma)
• Prostate cancer
• Pancreatic cancer
Current trend: DC vaccines loaded with patient-specific tumor mutations (neoantigens) combined with drugs that "release the brakes" on the immune system (checkpoint inhibitors).
Bottom line: As of 2025, DC vaccines have demonstrated both safety and efficacy in brain tumors, skin cancer, and lung cancer — evidence that personalized cancer vaccination is a maturing field.
Wang et al., Cancer Biol Med, 2025 • ClinicalTrials.govNewly diagnosed brain cancer (glioblastoma) patients were tested with the DC vaccine DCVax-L (prepared from the patient's own tumor tissue) added to standard of care.
In the patient subgroup with the MGMT gene "silenced" — about the better-prognosis 40% of glioblastoma cases:
• Median survival: vaccine group 30.2 months, control 21.3 months (Hazard Ratio 0.74; P=0.027 — statistically significant)
Across the full patient population:
• 5-year survival: 13.0% vs 5.7% favoring vaccine
• 4-year survival: 15.7% vs 9.9% favoring vaccine
Bottom line: This is the first Phase 3-level evidence that DC vaccines extend life in glioblastoma — one of the most aggressive brain tumors. While standard chemotherapy alone tops out at 21 months, adding the vaccine can take it past 30 months.
Liau et al., JAMA Oncol, 2023; 9(1):112-121Dendritic cells act as "teachers" of T cells through the foundational 3-signal model of immunology:
① Target information: the DC presents the tumor antigen (MHC molecule + peptide → T cell receptor) — "will you recognize this tumor?"
② Activation confirmation: costimulator molecules (CD80/86 ↔ CD28) — "fire away, don't stand down"
③ Direction signal: the cytokine IL-12 — "go cytotoxic killer, not antibody-helper"
Bottom line: When all three signals fire together, tumor-specific killer T cells and long-lived memory responses are formed. This is the molecular foundation of personalized cancer vaccines; DC therapy is engineered to deliver these three signals in the correct order.
Banchereau & Steinman, Nature, 1998; 392:245-252Click cards for details
DC vaccines have one of the safest profiles among cancer immunotherapies. Their autologous nature (made from the patient's own cells) and controlled immune stimulation are the foundation of this safety.
Manufactured from the patient's own monocytes — no rejection or GvHD risk. Personally matched safety profile.
Controlled antigen presentation makes cytokine release syndrome (CRS) extremely rare. Unlike CAR-T, no risk of acute physical reactions.
Clinical trials have not reported central nervous system side effects with DC vaccines. Safe to administer throughout the treatment course.
The most commonly reported side effects are injection-site reactions and mild flu-like symptoms — all transient.
Personalized product prepared in closed manufacturing systems under international cGMP standards. Sterility and potency are verified for every dose.
T-cell training is directed against tumor-specific antigens — healthy tissue is not targeted, minimizing off-target toxicity.
DC vaccines drive the formation of anti-tumor memory T cells, offering the potential for long-term protection after treatment.
Kantoff et al., NEJM 2010 • Liau et al., JAMA Oncol 2023 • Pinho et al., Front Immunol 2023 • mRNA vs DC vaccines meta-analysis (60 trials, n=1777), 2024
There are several routes to "teach" a dendritic cell about the patient's tumor antigen. Each strategy carries distinct advantages in specificity, polyvalence, and personalization.
Patient tumor tissue is fragmented and loaded onto DCs. Polyvalent approach — covers both known and unknown antigens simultaneously.
Polyvalent
Defined tumor antigen peptides such as HER2, MUC1, NY-ESO-1, WT1 are loaded onto DCs. Defined antigen with standardized manufacturing advantage.
Defined Antigen
mRNA encoding the tumor antigen is delivered to the DC cytoplasm via electric pulse. Endogenous presentation, cross- presentation, and rapid personalization.
Rapid Personalization
Tumor cell and DC are merged via polyethylene glycol or electrofusion to create a hybrid cell. The full tumor antigen repertoire combined with strong costimulation.
Hybrid Cell
Neoantigens derived from the patient's tumor somatic mutations are identified via WES + prediction algorithms. The most personal, most targeted approach.
Neoantigen
Antigen is delivered to DCs via vectors such as adenovirus, lentivirus, or MVA. High transduction efficiency and long-lasting antigen expression — particularly ideal for viral antigens.
Viral VectorThe dendritic cell, in its teacher role, presents tumor antigens to CIK effector cells. This bidirectional interaction creates an anti-tumor response stronger than either modality could achieve alone.
Captures tumor-associated antigens, processes them, and prepares them for presentation via MHC molecules.
The DC presents processed tumor antigens to CIK cells. The bidirectional interaction increases IL-12 release and amplifies cytotoxicity.
CIK cells, now armed with antigen information, deliver targeted cytotoxicity through both NKG2D- and TCR-mediated pathways.
Lin et al., Immunol Lett 2017 • Jiang et al., J Transl Med 2024
Genkord is one of the rare facilities producing both DC and CIK cells in its own cGMP-certified laboratory.
We prepare dendritic cell vaccines individually for each patient in our own cGMP-certified laboratory. Local production, global quality.
End-to-end personalized production starting from the patient's own monocytes. The antigen-loading strategy is optimized per patient.
From apheresis to maturation, from quality control to clinical application — every step of DC vaccine production is managed under one roof.
All cGMP requirements for cellular products are met: closed-system manufacturing, sterility testing, potency calibration.
NK, CIK, and Dendritic Cell — we are one of the rare facilities in Türkiye producing this triple cellular immunotherapy spectrum under one roof.
DC vaccines are being studied in a wide range of indications, particularly glioblastoma, prostate cancer, melanoma, lung, colorectal, and pancreatic cancer. Best results have been observed in patients with low tumor burden (minimal residual disease) and as an adjuvant after standard treatments. The patient's immune system is expected to be relatively intact.
The process begins with apheresis (leukapheresis) to collect peripheral blood. CD14+ monocytes are isolated and cultured for 5 days in GM-CSF + IL-4 to differentiate into immature DCs. The patient's tumor antigen is then loaded (lysate, peptide, mRNA, etc.), and the cells are matured for another 2 days with the maturation cocktail (TNF-α + IL-1β + IL-6 + PGE₂). The vaccine is aliquoted and frozen at the end of ~7 days.
It depends on the clinical protocol, but a typical regimen is 3-6 priming doses (weekly or biweekly) followed by maintenance doses (monthly or every 3 months). Some studies administer 10-12 doses in total. The route can be intradermal, subcutaneous, or intranodal.
The safety profile of DC vaccines is significantly better than chemotherapy and CAR-T. The most common side effects are:
• Transient redness and tenderness at the injection site
• Mild fever or flu-like symptoms (typically 24-48 hours)
• Fatigue
Cytokine release syndrome (CRS) and neurotoxicity are very rare.
Yes — DC vaccines are being combined with CIK cells (DC-CIK combination — see the synergy section above), checkpoint inhibitors (anti-PD-1, anti-CTLA-4), and chemotherapy. Combination overcomes immune suppression mechanisms and converts the priming effect of DCs into a more powerful effector response.
The first DC-based cancer vaccine, Sipuleucel-T (Provenge®), was approved by the FDA in 2010 for prostate cancer — a proof-of-concept milestone for the field. In other indications, DC vaccines are actively studied in Phase II and Phase III trials, with some receiving conditional/restricted approvals from health authorities. Genkord aims to deliver personalized DC vaccines at clinical-grade standards.
Reach out to our team for information on dendritic cell vaccines, R&D collaborations, or clinical study partnerships.
